Cost of treating otitis media in Australia

Penelope S. Taylor, Isabel Faeth, Michael K. Marks, Chris B. Del Mar, Susan A. Skull, M. Lynne Pezzullo, Susan M. Havyatt, Harvey L. Coates

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)

Abstract

Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost-effectiveness of prevention or amelioration of OM would be useful.

Original languageEnglish
Pages (from-to)133-141
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume9
Issue number2
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Otitis Media
Costs and Cost Analysis
Health Care Costs
Anti-Bacterial Agents
Hospital Emergency Service
Cost of Illness
Pediatric Hospitals
Quality-Adjusted Life Years
Microbial Drug Resistance
Hearing Loss
Tertiary Care Centers
General Practitioners
Cost-Benefit Analysis
Comorbidity
Primary Health Care
Pathology
Incidence
Health
Research
Pharmaceutical Preparations

Cite this

Taylor, P. S., Faeth, I., Marks, M. K., Del Mar, C. B., Skull, S. A., Pezzullo, M. L., ... Coates, H. L. (2009). Cost of treating otitis media in Australia. Expert Review of Pharmacoeconomics and Outcomes Research, 9(2), 133-141. https://doi.org/10.1586/erp.09.6
Taylor, Penelope S. ; Faeth, Isabel ; Marks, Michael K. ; Del Mar, Chris B. ; Skull, Susan A. ; Pezzullo, M. Lynne ; Havyatt, Susan M. ; Coates, Harvey L. / Cost of treating otitis media in Australia. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2009 ; Vol. 9, No. 2. pp. 133-141.
@article{8425031c5f904dab892c8b548ae2bca6,
title = "Cost of treating otitis media in Australia",
abstract = "Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost-effectiveness of prevention or amelioration of OM would be useful.",
author = "Taylor, {Penelope S.} and Isabel Faeth and Marks, {Michael K.} and {Del Mar}, {Chris B.} and Skull, {Susan A.} and Pezzullo, {M. Lynne} and Havyatt, {Susan M.} and Coates, {Harvey L.}",
year = "2009",
month = "4",
doi = "10.1586/erp.09.6",
language = "English",
volume = "9",
pages = "133--141",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "2",

}

Taylor, PS, Faeth, I, Marks, MK, Del Mar, CB, Skull, SA, Pezzullo, ML, Havyatt, SM & Coates, HL 2009, 'Cost of treating otitis media in Australia' Expert Review of Pharmacoeconomics and Outcomes Research, vol. 9, no. 2, pp. 133-141. https://doi.org/10.1586/erp.09.6

Cost of treating otitis media in Australia. / Taylor, Penelope S.; Faeth, Isabel; Marks, Michael K.; Del Mar, Chris B.; Skull, Susan A.; Pezzullo, M. Lynne; Havyatt, Susan M.; Coates, Harvey L.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 9, No. 2, 04.2009, p. 133-141.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cost of treating otitis media in Australia

AU - Taylor, Penelope S.

AU - Faeth, Isabel

AU - Marks, Michael K.

AU - Del Mar, Chris B.

AU - Skull, Susan A.

AU - Pezzullo, M. Lynne

AU - Havyatt, Susan M.

AU - Coates, Harvey L.

PY - 2009/4

Y1 - 2009/4

N2 - Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost-effectiveness of prevention or amelioration of OM would be useful.

AB - Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost-effectiveness of prevention or amelioration of OM would be useful.

UR - http://www.scopus.com/inward/record.url?scp=68349146959&partnerID=8YFLogxK

U2 - 10.1586/erp.09.6

DO - 10.1586/erp.09.6

M3 - Article

VL - 9

SP - 133

EP - 141

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 2

ER -